Company News

Hoth Therapeutics, Weill Cornell Extend Acne Research

Investigating mechanism of action and safety of novel novel retinoic acid metabolism blocking agent.

Author Image

By: Christine Esposito

Editor-in-Chief

Biopharma company Hoth Therapeutics, Inc. is extending a research collaboration agreement with Weill Cornell Medicine to continue investigating the therapeutic mechanism of action and safety of HT-003, a novel retinoic acid metabolism blocking agent (RAMBA) for the treatment of acne. The single year agreement extension is based on positive results generated from a prior research agreement that support a therapeutic effect of HT-003 in key signaling pathways contributing to the development of acn...

Continue reading this story and get 24/7 access to Happi for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Happi Newsletters